Vaccine study reveals link between immunity and cells' starvation response

December 5, 2013, Emory University

One of the most effective vaccines in history has been the yellow fever vaccine, which was developed in the 1930s and has been administered to more than 500 million people.

Scientists at Emory Vaccine Center studying immune responses to the yellow fever vaccine have identified a gene whose activation in key immune cells is a sign of a robust response. The gene, called GCN2, encodes a protein involved in sensing amino acid starvation and regulates the process of autophagy, a response to starvation or stress within cells.

The findings highlight a link between antiviral defenses and an ancient way that cells adapt to scarcity, and could help researchers develop vaccines against challenging viruses such as HIV or dengue. The results suggest that vaccine additives (called adjuvants) that are effective in stimulating GCN2 and autophagy would be especially potent in stimulating long-lasting immunity.

The results are scheduled for publication Thursday by the journal Science.

"This is an example of taking a system-wide approach to studying vaccine responses, and how it can reveal new insights about the functioning of the immune system," says senior author Bali Pulendran, PhD. "We were not thinking about the stress response pathway and immunity until our analysis pointed us in that direction."

Pulendran is Charles Howard Candler professor of pathology and laboratory medicine at Emory University School of Medicine and a researcher at Yerkes National Primate Research Center. The co-first authors of the paper are postdoctoral fellows Ravesh Ravindran, PhD and Noor Khan, PhD.

A single dose of the live attenuated viral yellow fever vaccine can protect against disease-causing forms of the virus for decades. Investigators led by Pulendran have been dissecting immune responses to the yellow fever vaccine, taking a genome-wide "systems biology" approach.

They started by looking at all the genes that are turned on a few days after human volunteers were vaccinated against yellow fever and asked: which genes' activations are the signatures of especially strong immune responses later? In particular, Pulendran and his colleagues looked for responses by CD8 "killer" T cells, which are important for eliminating virally-infected cells from the body.

One gene that stuck out was GCN2, because it was induced quickly after vaccination and was a sign that the immune system would later respond with lots of CD8 T cells.

GCN2 was known to be a sensor inside cells that detects low levels of , the building blocks for proteins. GCN2 regulates the process of autophagy, in which cells respond to starvation or stress by ceasing growth and beginning to digest themselves.

In the Science paper, Pulendran and his colleagues show that GCN2's function is especially critical in , whose job is to "present" information about viruses and other pathogens to the rest of the immune system. Dendritic cells lacking GCN2 are less able to activate CD8 T cells, they found.

Mice that lacked GCN2 had impaired responses to yellow fever vaccine and to inhaled influenza vaccine, the researchers found.

They also found that infection with leads to a depletion of amino acids within dendritic cells. When viruses infect dendritic cells, it appears that the viruses start using up the building materials on hand. This tips the dendritic into autophagy and raising an alarm with the rest of the , Pulendran says.

"This may have evolved as a mechanism of pathogen sensing that is capable of detecting the footprints of a pathogen, such as depleted amino acids in a local microenvironment," he says.

Explore further: Scientists find the invisibility cloak that shields HIV-1 from the immune system

More information: "Vaccine Activation of the Nutrient Sensor GCN2 in Dendritic Cells Enhances Antigen Presentation" Science, 2013.

Review on history of yellow fever vaccine: www.nature.com/nri/journal/v9/n10/abs/nri2629.html

Related Stories

Scientists find the invisibility cloak that shields HIV-1 from the immune system

November 21, 2013
Of the two major types of HIV, only one, HIV-1, typically causes AIDS in infected people who don't receive treatment. A study published by Cell Press November 21st in the journal Immunity reveals how HIV-1 escapes detection ...

Quick test can predict immune responses to flu shots

July 11, 2011
Researchers at the Emory Vaccine Center have developed a method for predicting whether someone will produce high levels of antibodies against a flu shot a few days after vaccination.

Malaria vaccine offers new mode of protection against disease

November 29, 2013
(Medical Xpress)—A novel malaria vaccine developed at Oxford University has shown promising results in the first clinical trial to test whether it can protect people against the mosquito-borne disease.

Experimental HIV vaccine targets virus envelope protein

November 27, 2013
AIDS research has investigated many strategies to tackle the HIV virus. Now, a new type of vaccine developed within the EU-funded project EuroNeut-41, targets an HIV envelope protein called the gp41. The protein is directly ...

Recommended for you

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.